Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“For those diagnosed with HER2+ metastatic breast cancer, rapid disease progression in the front-line setting is a significant challenge, despite a well-established standard of care.
Until recently, there have been limited advancements for these patients. That’s why I’m pleased to share positive topline progression-free survival results from a Phase 3 study evaluating our tyrosine kinase inhibitor in combination with first-line standard-of-care maintenance therapy
Thank you to the patients and investigators who contributed to this important study as we continue to advance research with the goal of transforming care for people living with breast cancer.”
Proceed to the video attached to the post.
More posts featuring Chris Boshoff.